Company intelligence / Profile preview

AVM Biotechnology

Seattle, Washington, United Statesavmbiotech.com ↗

Ownership: Private
Employees: ~30
Development stage: Preclinical

Overview

AVM Biotechnology has advanced its lead product AVM0703 into pivotal Phase 2 clinical trials for relapsed/refractory Non-Hodgkin’s Lymphoma and leukemia. The drug has shown promising safety and efficacy signals in both clinical trial participants and expanded access/compassionate use cases across multiple cancer types. Over twenty-eight patients with solid tumors or blood cancers have been treated under these programs with good tolerability reported. The company also holds INDs for ARDS related to viral infections such as COVID‑19[6][7][10].

Therapeutic areas: OncologyPulmonologyImmunology
Modalities: Small molecule (high-dose dexamethasone formulation)Cell therapy (mobilization of endogenous immune cells)
Industry: Biotech

Drug pipeline

2 assets

AVM0703

1 more asset in the full pipeline.

Request access →

Partnerships

National Cancer Institute / NIH SBIR grants[4][6]No major pharma partnerships disclosed as of current data.

Beyond the preview

Go deeper on AVM Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVM Biotechnology.

Explore the full profile